JPWO2020104531A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020104531A5 JPWO2020104531A5 JP2021527213A JP2021527213A JPWO2020104531A5 JP WO2020104531 A5 JPWO2020104531 A5 JP WO2020104531A5 JP 2021527213 A JP2021527213 A JP 2021527213A JP 2021527213 A JP2021527213 A JP 2021527213A JP WO2020104531 A5 JPWO2020104531 A5 JP WO2020104531A5
- Authority
- JP
- Japan
- Prior art keywords
- mva
- recombinant mva
- herv
- pharmaceutical composition
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 108020004707 nucleic acids Proteins 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 42
- 239000000427 antigen Substances 0.000 claims description 25
- 102000038129 antigens Human genes 0.000 claims description 25
- 108091007172 antigens Proteins 0.000 claims description 25
- 230000001965 increased Effects 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000004083 survival Effects 0.000 claims description 18
- 241000192019 Human endogenous retrovirus K Species 0.000 claims description 17
- 230000002601 intratumoral Effects 0.000 claims description 15
- 230000028709 inflammatory response Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 208000007089 Vaccinia Diseases 0.000 claims description 13
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 13
- 230000003042 antagnostic Effects 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 13
- 239000000556 agonist Substances 0.000 claims description 12
- 102000002627 4-1BB Ligand Human genes 0.000 claims description 10
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 10
- 108010029697 CD40 Ligand Proteins 0.000 claims description 10
- 102100003729 CD40LG Human genes 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 102100003649 ACP3 Human genes 0.000 claims description 8
- 102100011842 CEACAM5 Human genes 0.000 claims description 8
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 8
- 102100016662 ERBB2 Human genes 0.000 claims description 8
- 101700025368 ERBB2 Proteins 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 8
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 8
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims description 8
- 230000002708 enhancing Effects 0.000 claims description 7
- 230000001177 retroviral Effects 0.000 claims description 7
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 6
- 210000004027 cells Anatomy 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 102100007290 CD274 Human genes 0.000 claims description 4
- 101710012053 CD274 Proteins 0.000 claims description 4
- 102100005310 CTLA4 Human genes 0.000 claims description 4
- 101700054183 CTLA4 Proteins 0.000 claims description 4
- 102100011898 FOLR1 Human genes 0.000 claims description 4
- 101700050183 FOLR1 Proteins 0.000 claims description 4
- 102100016384 HAVCR2 Human genes 0.000 claims description 4
- 101710004393 HAVCR2 Proteins 0.000 claims description 4
- 102100017213 LAG3 Human genes 0.000 claims description 4
- 108060004270 LAG3 Proteins 0.000 claims description 4
- 108010008707 Mucin-1 Proteins 0.000 claims description 4
- 102000007298 Mucin-1 Human genes 0.000 claims description 4
- 102100006759 PRAME Human genes 0.000 claims description 4
- 108060006580 PRAME Proteins 0.000 claims description 4
- 102100013504 RPL17 Human genes 0.000 claims description 4
- 108060007796 SPATA2 Proteins 0.000 claims description 4
- 108010002687 Survivin Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000000969 carrier Substances 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 102000000763 Survivin Human genes 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 102100007326 BIRC5 Human genes 0.000 description 2
- 102000033180 ERVK-6 Human genes 0.000 description 2
- 101710038044 ERVK-6 Proteins 0.000 description 2
- 101710027967 ERVW-1 Proteins 0.000 description 2
- 101710023234 Segment 5 Proteins 0.000 description 2
- 101700028070 VPX Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 102000008187 gag Gene Products Human genes 0.000 description 2
- 108010060555 gag Gene Products Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010071967 protein K Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- 102100006878 ERVK-11 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
Description
実施形態５２は、実施形態２８～３２のいずれか１つに記載の組み換えＭＶＡ、実施形態２７に記載のワクチン、実施形態２６に記載の医薬組成物、実施形態３３～４０のいずれか１つに記載の併用医薬であって、がん性腫瘍を有する対象において、腫瘍サイズを縮小させ、及び／または生存率を上昇させる方法で用いるものであり、その方法が、実施形態２８～３２に記載の組み換えＭＶＡ、実施形態２７に記載のワクチン、実施形態２６に記載の医薬組成物、または実施形態３３～４０のいずれか１つに記載の併用医薬をその対象に静脈内投与及び腫瘍内投与することを含み、前記静脈内投与及び腫瘍内投与により、１）ＴＡＡをコードする第１の核酸と、抗原４－１ＢＢＬをコードする第２の核酸とを含む組み換えＭＶＡウイルス、２）ＴＡＡをコードする第１の核酸と、抗原ＣＤ４０Ｌをコードする第２の核酸とを含む組み換えＭＶＡウイルス、または３）ＴＡＡをコードする第１の核酸と、抗原４－１ＢＢＬをコードする第２の核酸と、抗原ＣＤ４０Ｌをコードする第３の核酸とを含む組み換えＭＶＡウイルスの群から選択したいずれかのＭＶＡを非静脈内投与または非腫瘍内投与する場合と比べて、その対象の腫瘍の縮小が増大し、及び／または全生存率が上昇するものである。前記静脈内投与及び腫瘍内投与は、当業者には明らかなように、同時または異なる時点に行うことができる。
なお、本願は、特許請求の範囲に記載の発明に関するものであるが、他の態様として以下も包含し得る。
１．がん性腫瘍を有する対象において、腫瘍サイズを縮小させ、及び／または生存率を上昇させる方法であって、前記方法が、腫瘍関連抗原（ＴＡＡ）をコードする第１の核酸と、４－１ＢＢＬをコードする第２の核酸とを含む組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に腫瘍内投与することを含み、前記組み換えＭＶＡを腫瘍内投与すると、ＴＡＡ及び抗原４－１ＢＢＬをコードする第１及び第２の核酸を含む組み換えＭＶＡウイルスを非腫瘍内注射する場合と比べて、前記がん性腫瘍における炎症応答が増強され、前記対象の腫瘍の縮小が増大し、及び／または全生存率が上昇する前記方法。
２．がん性腫瘍を有する対象において、腫瘍サイズを縮小させ、及び／または生存率を上昇させる方法であって、前記方法が、腫瘍関連抗原（ＴＡＡ）をコードする第１の核酸と、４－１ＢＢＬをコードする第２の核酸とを含む組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に静脈内投与することを含み、前記組み換えＭＶＡを静脈内投与すると、ＴＡＡ及び抗原４－１ＢＢＬをコードする第１及び第２の核酸を含む組み換えＭＶＡウイルスを非静脈内注射する場合と比べて、ナチュラルキラー（ＮＫ）細胞応答が増強され、前記ＴＡＡに特異的なＣＤ８ Ｔ細胞応答が増強される前記方法。
３．がん性腫瘍を有する対象において、腫瘍サイズを縮小させ、及び／または生存率を上昇させる方法であって、前記方法が、腫瘍関連抗原（ＴＡＡ）をコードする第１の核酸と、４－１ＢＢＬをコードする第２の核酸とを含む組み換え改変ワクシニアアンカラ（ＭＶＡ）を含む前記対象に投与することを含み、前記組み換えＭＶＡを投与すると、組み換えＭＶＡ及び抗原４－１ＢＢＬを単独で投与する場合と比べて、前記対象の腫瘍の縮小が増大し、及び／または全生存率が上昇する前記方法。
４．対象のがん性腫瘍における炎症応答の増強を誘導する方法であって、前記方法が、第１の異種の腫瘍関連抗原（ＴＡＡ）をコードする第１の核酸と、抗原４－１ＢＢＬをコードする第２の核酸とを含む組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に腫瘍内投与することを含み、前記組み換えＭＶＡを腫瘍内投与すると、異種の腫瘍関連抗原及び抗原４－１ＢＢＬをコードする第１及び第２の核酸を含む組み換えＭＶＡウイルスの非腫瘍内注射によって生じる炎症応答と比べて、前記腫瘍における炎症応答が増強される前記方法。
５．前記対象が、ヒトである、上記１に記載の方法。
６．前記ＴＡＡが、腫瘍細胞で発現する内在性レトロウイルス（ＥＲＶ）タンパク質である、上記１に記載の方法。
７．前記ＥＲＶタンパク質が、ヒト内在性レトロウイルスＫ（ＨＥＲＶ－Ｋ）ファミリーに由来し、ＨＥＲＶ－Ｋエンベロープタンパク質及びＨＥＲＶ－Ｋ ｇａｇタンパク質から選択されている、上記６に記載の方法。
８．前記ＴＡＡが、がん胎児性抗原（ＣＥＡ）、ムチン１細胞表面関連（ＭＵＣ－１）、前立腺酸性ホスファターゼ（ＰＡＰ）、前立腺特異抗原（ＰＳＡ）、ヒト上皮細胞成長因子受容体２（ＨＥＲ－２）、サバイビン、チロシン関連タンパク質１（ＴＲＰ１）、チロシン関連タンパク質１（ＴＲＰ２）、Ｂｒａｃｈｙｕｒｙ、ＰＲＡＭＥ、ＦＯＬＲ１、ＨＥＲＶ－Ｋ－ｅｎｖ、ＨＥＲＶ－Ｋ－ｇａｇ、ｐ１５、ＭＥＬ及びこれらを組み合わせたものからなる群から選択されている、上記１に記載の方法。
９．がん性腫瘍を有する対象において、腫瘍サイズを縮小させ、及び／または生存率を上昇させる方法であって、前記方法が、内在性レトロウイルス（ＥＲＶ）タンパク質をコードする第１の核酸と、４－１ＢＢＬをコードする第２の核酸とを含む組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に投与することを含み、前記組み換えＭＶＡを投与すると、組み換えＭＶＡ及び抗原４－１ＢＢＬを単独で投与する場合と比べて、前記対象の腫瘍の縮小が増大し、及び／または全生存率が上昇する前記方法。
１０．前記ＥＲＶタンパク質が、ヒト内在性レトロウイルスタンパク質Ｋ（ＨＥＲＶ－Ｋ）ファミリー由来である、上記９に記載の方法。
１１．前記レトロウイルスタンパク質Ｋが、ＨＥＲＶ－Ｋエンベロープタンパク質及びＨＥＲＶ－Ｋ－ｇａｇタンパク質から選択されている、上記１０に記載の方法。
１２．前記組み換えＭＶＡが、抗原ＣＤ４０Ｌをコードする第３の核酸をさらに含む、上記１に記載の方法。
１３．少なくとも１つの免疫チェックポイント分子アンタゴニストまたは免疫チェックポイント分子アゴニストを前記対象に投与することをさらに含む、上記１に記載の方法。
１４．前記免疫チェックポイント分子アンタゴニストまたは前記免疫チェックポイント分子アゴニストが、ＣＴＬＡ－４、ＰＤ－１、ＰＤ－Ｌ１、ＬＡＧ－３、ＴＩＭ－３及びＩＣＯＳのアンタゴニストまたはアゴニストから選択される、上記１３に記載の方法。
１５．前記免疫チェックポイント分子アンタゴニストが、抗体である、上記１４に記載の方法。
１６．がんの治療で用いる組み換え改変ワクシニアアンカラ（ＭＶＡ）であって、ａ）腫瘍関連抗原（ＴＡＡ）をコードする第１の核酸と、ｂ）４－１ＢＢＬをコードする第２の核酸とを含み、前記組み換えＭＶＡを腫瘍内投与すると、前記組み換えＭＶＡを非腫瘍内注射する場合と比べて、そのヒト患者のがん性腫瘍における炎症応答が増強され、前記がん性腫瘍のサイズが縮小し、及び／または全生存率が上昇する前記組み換えＭＶＡ。
１７．ｃ）ＣＤ４０Ｌをコードする第３の核酸をさらに含む、上記１６に記載の用途用の組み換えＭＶＡ。
１８．前記ＴＡＡが、内在性レトロウイルス（ＥＲＶ）タンパク質である、上記１６に記載の用途用の組み換えＭＶＡ。
１９．前記ＥＲＶタンパク質が、ヒト内在性レトロウイルスＫ（ＨＥＲＶ－Ｋ）ファミリーに由来し、ＨＥＲＶ－Ｋ－ｅｎｖ及びＨＥＲＶ－Ｋ－ｇａｇから選択されている、上記１８に記載の用途用の組み換えＭＶＡ。
２０．前記ＴＡＡが、がん胎児性抗原（ＣＥＡ）、ムチン１細胞表面関連（ＭＵＣ－１）、前立腺酸性ホスファターゼ（ＰＡＰ）、前立腺特異抗原（ＰＳＡ）、ヒト上皮細胞成長因子受容体２（ＨＥＲ－２）、サバイビン、チロシン関連タンパク質１（ＴＲＰ１）、チロシン関連タンパク質１（ＴＲＰ２）、Ｂｒａｃｈｙｕｒｙ、ＦＯＬＲ１、ＰＲＡＭＥ、ＨＥＲＶ－Ｋ－ｅｎｖ、ＨＥＲＶ－Ｋ－ｇａｇ、ｐ１５、ＭＥＬ及びこれらを組み合わせたものからなる群から選択されている、上記１６に記載の用途用の組み換えＭＶＡ。
２１．がんである対象を治療するための組み換え改変ワクシニアアンカラ（ＭＶＡ）であって、（ａ）腫瘍関連抗原（ＴＡＡ）をコードする第１の核酸と、（ｂ）４－１ＢＢＬをコードする第２の核酸とを含む前記組み換えＭＶＡ。
２２．前記ＴＡＡが、ヒト内在性レトロウイルスＫ（ＨＥＲＶ－Ｋ）ファミリーのＥＲＶタンパク質である、上記２１に記載の組み換えＭＶＡ。
２３．前記ＥＲＶタンパク質が、ＨＥＲＶ－Ｋ ｅｎｖタンパク質及びＨＥＲＶ－Ｋ ｇａｇタンパク質から選択されている、上記２２に記載の組み換えＭＶＡ。
２４．ｃ）ＣＤ４０Ｌをコードする第３の核酸をさらに含む、上記２３に記載の組み換えＭＶＡ。
２５．（ａ）上記２４に記載の組み換えＭＶＡと、（ｂ）少なくとも１つの免疫チェックポイント分子アンタゴニストまたは免疫チェックポイント分子アゴニストとを含む併用医薬。
２６．前記免疫チェックポイント分子アンタゴニストまたは前記免疫チェックポイント分子アゴニストが、ＣＴＬＡ－４、ＰＤ－１、ＰＤ－Ｌ１、ＬＡＧ－３、ＴＩＭ－３及びＩＣＯＳのアンタゴニストまたはアゴニストから選択されている、上記２５に記載の併用医薬。
２７．がん性腫瘍を有する対象において、腫瘍サイズを縮小させ、及び／または生存率を上昇させる方法であって、前記方法が、腫瘍関連抗原（ＴＡＡ）をコードする第１の核酸と、４－１ＢＢＬをコードする第２の核酸と、ＣＤ４０Ｌをコードする第３の核酸とを含む組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に投与することを含み、前記組み換えＭＶＡを投与すると、組み換えＭＶＡ、抗原４－１ＢＢＬ及び抗原ＣＤ４０Ｌを単独で投与する場合と比べて、前記対象の腫瘍の縮小が増大し、及び／または全生存率が上昇する前記方法。
２８．対象のがん性腫瘍における炎症応答の増強を誘導する方法であって、前記方法が、第１の異種の腫瘍関連抗原（ＴＡＡ）をコードする第１の核酸と、抗原４－１ＢＢＬをコードする第２の核酸と、抗原ＣＤ４０Ｌをコードする第３の核酸とを含む組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に腫瘍内投与することを含み、前記組み換えＭＶＡを腫瘍内投与すると、異種の腫瘍関連抗原をコードする第１の核酸と、抗原４－１ＢＢＬをコードする第２の核酸と、抗原ＣＤ４０Ｌをコードする第３の核酸とを含む組み換えＭＶＡウイルスの非腫瘍内注射によって生じる炎症応答と比べて、前記腫瘍における炎症応答が増強される前記方法。
２９．前記組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に静脈内投与することを含む、上記２７に記載の方法。
３０．前記組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に腫瘍内投与することを含む、上記２７に記載の方法。
３１．前記組み換え改変ワクシニアアンカラ（ＭＶＡ）を前記対象に静脈内投与及び腫瘍内投与することを含む、上記２７に記載の方法。
３２．前記静脈内投与と前記腫瘍内投与とを異なる時点に行う、上記３１に記載の方法。
Embodiment 52 is a recombinant MVA according to any one of embodiments 28-32, a vaccine according to embodiment 27, a pharmaceutical composition according to embodiment 26, any one of embodiments 33-40. A pharmaceutical combination as described for use in a method of reducing tumor size and/or increasing survival in a subject with a cancerous tumor, the method comprising any of embodiments 28-32. intravenously and intratumorally administering to the subject recombinant MVA, the vaccine of embodiment 27, the pharmaceutical composition of embodiment 26, or the pharmaceutical combination of any one of embodiments 33-40. wherein the intravenous and intratumoral administration produces 1) a recombinant MVA virus comprising a first nucleic acid encoding a TAA and a second nucleic acid encoding the antigen 4-1BBL, 2) a second nucleic acid encoding a TAA and a second nucleic acid encoding the antigen CD40L, or 3) a first nucleic acid encoding a TAA, a second nucleic acid encoding the antigen 4-1BBL, and the antigen CD40L. increased tumor shrinkage in the subject compared to non-intravenous or non-intratumoral administration of any MVA selected from the group of recombinant MVA viruses comprising a third nucleic acid encoding and/or It increases overall survival. Said intravenous administration and intratumoral administration can be carried out at the same time or at different times, as will be appreciated by those skilled in the art.
Although the present application relates to the invention described in the claims, it can also include the following as other aspects.
1. A method of reducing tumor size and/or increasing survival in a subject with a cancerous tumor, said method comprising: a first nucleic acid encoding a tumor-associated antigen (TAA); intratumorally administering to said subject recombinant modified vaccinia Ankara (MVA) comprising a second nucleic acid encoding enhanced inflammatory response in said cancerous tumor, increased tumor shrinkage and/or increased overall survival in said subject compared to non-intratumoral injection of a recombinant MVA virus comprising a second nucleic acid the above method.
2. A method of reducing tumor size and/or increasing survival in a subject with a cancerous tumor, said method comprising: a first nucleic acid encoding a tumor-associated antigen (TAA); intravenously administering to said subject recombinant modified vaccinia Ankara (MVA) comprising a second nucleic acid encoding Said method wherein a natural killer (NK) cell response is enhanced and said TAA-specific CD8 T cell response is enhanced compared to non-intravenous injection of a recombinant MVA virus comprising a second nucleic acid.
3. A method of reducing tumor size and/or increasing survival in a subject with a cancerous tumor, said method comprising: a first nucleic acid encoding a tumor-associated antigen (TAA); administering to the subject a recombinant modified vaccinia Ankara (MVA) comprising a second nucleic acid encoding wherein said subject has increased tumor shrinkage and/or increased overall survival.
4. A method of inducing an enhanced inflammatory response in a cancerous tumor of a subject, said method comprising a first nucleic acid encoding a first heterologous tumor-associated antigen (TAA) and encoding antigen 4-1BBL intratumorally administering to said subject recombinant modified vaccinia Ankara (MVA) comprising a second nucleic acid, wherein upon intratumoral administration of said recombinant MVA, a heterologous tumor-associated antigen and a first nucleic acid encoding antigen 4-1BBL and said method wherein an inflammatory response in said tumor is enhanced relative to the inflammatory response produced by non-intratumoral injection of a recombinant MVA virus comprising a second nucleic acid.
5. 2. The method of claim 1, wherein the subject is human.
6. 2. The method of claim 1, wherein the TAA is an endogenous retroviral (ERV) protein expressed in tumor cells.
7. 7. The method of claim 6, wherein said ERV protein is from the human endogenous retrovirus K (HERV-K) family and is selected from HERV-K envelope protein and HERV-K gag protein.
8. The TAAs are carcinoembryonic antigen (CEA), mucin 1 cell surface associated (MUC-1), prostatic acid phosphatase (PAP), prostate specific antigen (PSA), human epidermal growth factor receptor 2 (HER-2) ), survivin, tyrosine-related protein 1 (TRP1), tyrosine-related protein 1 (TRP2), Brachyury, PRAME, FOLR1, HERV-K-env, HERV-K-gag, p15, MEL and combinations thereof 1. The method of claim 1, wherein the method is selected from
9. 4. A method of reducing tumor size and/or increasing survival in a subject with a cancerous tumor, said method comprising: a first nucleic acid encoding an endogenous retroviral (ERV) protein; - administering to the subject a recombinant modified vaccinia Ankara (MVA) comprising a second nucleic acid encoding 1BBL, wherein administering the recombinant MVA and administering the recombinant MVA and the antigen 4-1BBL alone; Said method, wherein said subject's tumor shrinkage is increased and/or overall survival is increased in comparison.
10. 10. The method of claim 9, wherein said ERV protein is from the human endogenous retroviral protein K (HERV-K) family.
11. 11. The method of claim 10, wherein said retroviral protein K is selected from HERV-K envelope protein and HERV-K-gag protein.
12. 2. The method of claim 1, wherein said recombinant MVA further comprises a third nucleic acid encoding the antigen CD40L.
13. 2. The method of claim 1, further comprising administering to said subject at least one immune checkpoint molecule antagonist or immune checkpoint molecule agonist.
14. 14. 14. 14 above, wherein said immune checkpoint molecule antagonist or said immune checkpoint molecule agonist is selected from antagonists or agonists of CTLA-4, PD-1, PD-L1, LAG-3, TIM-3 and ICOS. Method.
15. 15. The method of 14 above, wherein the immune checkpoint molecule antagonist is an antibody.
16. 1. A recombinant modified vaccinia Ankara (MVA) for use in the treatment of cancer, comprising a) a first nucleic acid encoding a tumor-associated antigen (TAA) and b) a second nucleic acid encoding 4-1BBL, intratumoral administration of the recombinant MVA enhances the inflammatory response and reduces the size of the cancerous tumor in the human patient compared to non-intratumoral injection of the recombinant MVA; and /or said recombinant MVA with increased overall survival.
17. c) A recombinant MVA for use according to 16 above, further comprising a third nucleic acid encoding CD40L.
18. 17. A recombinant MVA for use according to claim 16, wherein said TAA is an endogenous retroviral (ERV) protein.
19. 19. A recombinant MVA for use according to claim 18, wherein said ERV protein is from the human endogenous retrovirus K (HERV-K) family and is selected from HERV-K-env and HERV-K-gag.
20. The TAAs are carcinoembryonic antigen (CEA), mucin 1 cell surface associated (MUC-1), prostatic acid phosphatase (PAP), prostate specific antigen (PSA), human epidermal growth factor receptor 2 (HER-2) ), survivin, tyrosine-related protein 1 (TRP1), tyrosine-related protein 1 (TRP2), Brachyury, FOLR1, PRAME, HERV-K-env, HERV-K-gag, p15, MEL and combinations thereof 17. A recombinant MVA for use according to 16 above, which is selected from
21. A recombinant modified vaccinia Ankara (MVA) for treating a subject with cancer comprising: (a) a first nucleic acid encoding a tumor-associated antigen (TAA); and (b) a second nucleic acid encoding 4-1BBL. the recombinant MVA comprising a nucleic acid;
22. 22. The recombinant MVA of claim 21, wherein said TAA is an ERV protein of the human endogenous retrovirus K (HERV-K) family.
23. 23. The recombinant MVA of claim 22, wherein said ERV protein is selected from HERV-K env protein and HERV-K gag protein.
24. c) A recombinant MVA according to 23 above, further comprising a third nucleic acid encoding CD40L.
25. A pharmaceutical combination comprising (a) a recombinant MVA according to 24 above and (b) at least one immune checkpoint molecule antagonist or immune checkpoint molecule agonist.
26. 26. The method of claim 25, wherein said immune checkpoint molecule antagonist or immune checkpoint molecule agonist is selected from antagonists or agonists of CTLA-4, PD-1, PD-L1, LAG-3, TIM-3 and ICOS. concomitant medications.
27. A method of reducing tumor size and/or increasing survival in a subject with a cancerous tumor, said method comprising: a first nucleic acid encoding a tumor-associated antigen (TAA); and a third nucleic acid encoding CD40L, wherein administration of the recombinant MVA comprises administering to the subject a recombinant MVA, antigen 4- Said method, wherein said subject has increased tumor shrinkage and/or increased overall survival compared to administration of 1BBL and the antigen CD40L alone.
28. A method of inducing an enhanced inflammatory response in a cancerous tumor of a subject, said method comprising a first nucleic acid encoding a first heterologous tumor-associated antigen (TAA) and encoding antigen 4-1BBL intratumorally administering to said subject a recombinant modified vaccinia Ankara (MVA) comprising a second nucleic acid and a third nucleic acid encoding the antigen CD40L, wherein intratumoral administration of said recombinant MVA results in heterologous tumor-associated Compared to the inflammatory response generated by non-intratumoral injection of a recombinant MVA virus comprising a first nucleic acid encoding the antigen, a second nucleic acid encoding the antigen 4-1BBL, and a third nucleic acid encoding the antigen CD40L. , said method wherein an inflammatory response in said tumor is enhanced.
29. 28. The method of Claim 27, comprising intravenously administering said recombinant modified vaccinia Ankara (MVA) to said subject.
30. 28. The method of Claim 27, comprising intratumorally administering said recombinant modified vaccinia Ankara (MVA) to said subject.
31. 28. The method of claim 27, comprising intravenously and intratumorally administering said recombinant modified vaccinia Ankara (MVA) to said subject.
32. 32. The method of 31 above, wherein said intravenous administration and said intratumoral administration are performed at different times.
Claims (24)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18207238 | 2018-11-20 | ||
| EP18207238.9 | 2018-11-20 | ||
| US201962807720P | 2019-02-19 | 2019-02-19 | |
| US62/807,720 | 2019-02-19 | ||
| PCT/EP2019/081942 WO2020104531A1 (en) | 2018-11-20 | 2019-11-20 | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022507744A JP2022507744A (en) | 2022-01-18 |
| JPWO2020104531A5 true JPWO2020104531A5 (en) | 2022-10-26 |
Family
ID=68542659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527213A Pending JP2022507744A (en) | 2018-11-20 | 2019-11-20 | Therapy to treat cancer by intratumoral and / or intravenous administration of recombinant MVA encoding 4-1BBL (CD137L) and / or CD40L |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3883599A1 (en) |
| JP (1) | JP2022507744A (en) |
| KR (1) | KR20210094535A (en) |
| CN (1) | CN113056284A (en) |
| AU (1) | AU2019385665A1 (en) |
| BR (1) | BR112021009856A8 (en) |
| CA (1) | CA3119503A1 (en) |
| IL (1) | IL283187A (en) |
| MX (1) | MX2021005560A (en) |
| SG (1) | SG11202104918PA (en) |
| WO (1) | WO2020104531A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
| JP2023503858A (en) | 2019-11-20 | 2023-02-01 | バヴァリアン・ノルディック・アクティーゼルスカブ | 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA) Medical Use |
| KR20220106775A (en) * | 2019-11-20 | 2022-07-29 | 버베리안 노딕 에이/에스 | Recombinant MVA virus for intratumoral and/or intravenous administration for the treatment of cancer |
| US20230174653A1 (en) * | 2020-04-06 | 2023-06-08 | St. Jude Children's Research Hospital, Inc. | B7-h3 chimeric antigen receptors |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2023118563A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
| JPS63501765A (en) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | Antibody gene module assembly, antibodies produced thereby, and uses |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1990002809A1 (en) | 1988-09-02 | 1990-03-22 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| JP4146512B2 (en) | 1991-03-01 | 2008-09-10 | ダイアックス コープ． | Small protein |
| DK1471142T3 (en) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| CN1135181A (en) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | Alteration of immune response using pan Dr-binding peptides |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| NZ511055A (en) | 1998-10-05 | 2003-10-31 | Pharmexa As | Novel methods for therapeutic vaccination |
| CN100537773C (en) | 2000-11-23 | 2009-09-09 | 巴法里安诺迪克有限公司 | The improvement vaccinia ankara virus variant |
| ATE454447T1 (en) | 2001-11-30 | 2010-01-15 | Us Gov Health & Human Serv | PROSTATE-SPECIFIC ANTIGEN PEPTIDE AGONISTS AND THEIR USE |
| KR101042458B1 (en) | 2001-12-04 | 2011-06-16 | 벤처 테크놀로지스 에스디엔 비에이치디 | Flavivirus NS1 Subunit Vaccine |
| DK2367944T3 (en) | 2008-11-27 | 2019-04-15 | Bavarian Nordic As | PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| DK2800762T3 (en) | 2012-01-03 | 2018-04-16 | Us Health | NATIVE AND AGONISTIC CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| EP3639851A1 (en) | 2012-09-04 | 2020-04-22 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| JP6505016B2 (en) | 2012-10-28 | 2019-04-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | PR13.5 Promoter and Antibody Response for Robust T Cells |
| KR102499737B1 (en) * | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| KR20150135148A (en) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | PD-L1 Fused protein and use thereof |
| BR112018002172A8 (en) | 2015-07-31 | 2024-02-15 | Bavarian Nordic As | Promoters to enhance expression in poxviruses |
-
2019
- 2019-11-20 EP EP19802224.6A patent/EP3883599A1/en active Pending
- 2019-11-20 CA CA3119503A patent/CA3119503A1/en active Pending
- 2019-11-20 KR KR1020217014706A patent/KR20210094535A/en active Search and Examination
- 2019-11-20 MX MX2021005560A patent/MX2021005560A/en unknown
- 2019-11-20 JP JP2021527213A patent/JP2022507744A/en active Pending
- 2019-11-20 BR BR112021009856A patent/BR112021009856A8/en unknown
- 2019-11-20 WO PCT/EP2019/081942 patent/WO2020104531A1/en unknown
- 2019-11-20 SG SG11202104918PA patent/SG11202104918PA/en unknown
- 2019-11-20 AU AU2019385665A patent/AU2019385665A1/en active Pending
- 2019-11-20 CN CN201980076127.2A patent/CN113056284A/en active Pending
-
2021
- 2021-05-13 IL IL283187A patent/IL283187A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bausart et al. | Immunotherapy for glioblastoma: the promise of combination strategies | |
| CN109219445B (en) | Use of chimeric antigen receptor modified cells for the treatment of cancer | |
| Schlom | Therapeutic cancer vaccines: current status and moving forward | |
| Tsuji et al. | Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity | |
| US11059904B2 (en) | Compositions and methods for tumor transduction | |
| JP2022066311A5 (en) | ||
| Calzascia et al. | Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain | |
| KR20180094922A (en) | Methods and compositions for treating cancer | |
| JP2017515841A5 (en) | ||
| WO2018156791A1 (en) | Compositions and methods for tumor transduction | |
| KR20210094535A (en) | Methods of treating cancer by intratumoral and/or intravenous administration of recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L | |
| Yu et al. | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma | |
| Evaristo et al. | Cutting edge: engineering active IKKβ in T cells drives tumor rejection | |
| JPWO2020104531A5 (en) | ||
| Bronte et al. | Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase | |
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| Estevez-Ordonez et al. | Immunotherapy for pediatric brain and spine tumors: current state and future directions | |
| De Mare et al. | Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition | |
| WO2017120997A1 (en) | Transgenic lymphocyte co-expressing egfrviii chimeric antigen receptor and non-functional egfr and uses of the lymphocyte | |
| CN114867491A (en) | Recombinant MVA viruses for intratumoral and/or intravenous administration for the treatment of cancer | |
| WO2007058235A1 (en) | Fusion protein and use thereof for pharmaceutical purposes | |
| WO2023118508A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| RU2021117499A (en) | THERAPY FOR CANCER TREATMENT USING INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA ENCODING 4-1BBL (CD137L) AND/OR CD40L | |
| Azad et al. | Glioblastoma antigen discovery—foundations for immunotherapy | |
| JPWO2021099586A5 (en) |